Published in Endocrinology on October 16, 2003
Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A (2013) 1.70
Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem (2010) 1.57
The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol (2013) 1.48
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Sex steroid actions in male bone. Endocr Rev (2014) 1.26
Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res (2005) 1.23
Roles of transactivating functions 1 and 2 of estrogen receptor-alpha in bone. Proc Natl Acad Sci U S A (2011) 1.17
Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. J Clin Endocrinol Metab (2005) 1.17
Steroid receptor coactivator 2 is required for female fertility and mammary morphogenesis: insights from the mouse, relevance to the human. Nucl Recept Signal (2007) 1.06
Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J Bone Miner Res (2010) 1.04
The function of steroid receptor coactivator-1 in normal tissues and cancer. Int J Biol Sci (2012) 1.00
Impact of pregnancy-associated plasma protein-a deletion on the adult murine skeleton. J Bone Miner Res (2008) 0.99
Sex hormones and their receptors in bone homeostasis: insights from genetically modified mouse models. Osteoporos Int (2009) 0.98
Novel modeling of combinatorial miRNA targeting identifies SNP with potential role in bone density. PLoS Comput Biol (2012) 0.97
The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modified. Proc Natl Acad Sci U S A (2014) 0.90
The skeletal response to estrogen is impaired in female but not in male steroid receptor coactivator (SRC)-1 knock out mice. Bone (2007) 0.90
Skeletal consequences of deletion of steroid receptor coactivator-2/transcription intermediary factor-2. J Biol Chem (2009) 0.88
Distinct effects of loss of classical estrogen receptor signaling versus complete deletion of estrogen receptor alpha on bone. Bone (2011) 0.87
Single-cell genome-wide bisulfite sequencing uncovers extensive heterogeneity in the mouse liver methylome. Genome Biol (2016) 0.83
Deletion of Estrogen Receptor Beta in Osteoprogenitor Cells Increases Trabecular but Not Cortical Bone Mass in Female Mice. J Bone Miner Res (2015) 0.82
Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev (2017) 0.81
Sex steroids and bone health in men. Bonekey Rep (2012) 0.79
TGFβ inducible early gene-1 plays an important role in mediating estrogen signaling in the skeleton. J Bone Miner Res (2014) 0.79
A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice. J Bone Miner Res (2016) 0.77
Effects of sex steroids on bones and muscles: Similarities, parallels, and putative interactions in health and disease. Bone (2015) 0.77
Estrogens and Androgens Inhibit Association of RANKL with the Pre-osteoblast Membrane through Post-translational Mechanisms. J Cell Physiol (2017) 0.77
Soluble guanylate cyclase as a novel treatment target for osteoporosis. Endocrinology (2014) 0.76
Fine-Tuning Reception in the Bone: PPARgamma and Company. PPAR Res (2006) 0.75
Female Mice Lacking Estrogen Receptor-α in Hypothalamic Proopiomelanocortin (POMC) Neurons Display Enhanced Estrogenic Response on Cortical Bone Mass. Endocrinology (2016) 0.75
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Combinatorial control of gene expression by nuclear receptors and coregulators. Cell (2002) 8.01
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev (2002) 6.38
Osteoporosis: now and the future. Lancet (2011) 5.81
Retracted DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol (2007) 4.45
SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell (2002) 4.31
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res (2004) 4.02
Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev (2004) 3.74
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer (2009) 3.33
Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science (2008) 3.17
Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res (2005) 3.11
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell (2006) 3.09
Analysis of the human endogenous coregulator complexome. Cell (2011) 2.97
Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell (2004) 2.95
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol (2006) 2.95
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation (2002) 2.93
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Incidence of childhood distal forearm fractures over 30 years: a population-based study. JAMA (2003) 2.81
A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res (2008) 2.76
SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell (2007) 2.69
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol (2013) 2.69
Nuclear receptor coregulators and human disease. Endocr Rev (2007) 2.65
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol Cell (2007) 2.57
The expanding cosmos of nuclear receptor coactivators. Cell (2006) 2.57
Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science (2002) 2.53
Retracted Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell (2009) 2.48
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Mol Cell Biol (2002) 2.45
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A (2008) 2.39
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab (2010) 2.33
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2010) 2.31
Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell (2007) 2.31
Transoral robotic surgery: radical tonsillectomy. Arch Otolaryngol Head Neck Surg (2007) 2.28
SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell (2010) 2.18
Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res (2005) 2.15
Assessment of renal hemodynamics and function in pigs with 64-section multidetector CT: comparison with electron-beam CT. Radiology (2007) 2.14
Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res (2007) 2.11
Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res (2008) 2.07
AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res (2004) 2.07
Minireview: nuclear receptor coactivators--an update. Endocrinology (2002) 2.04
Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab (2006) 2.04
The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev (2005) 2.03
Age-dependence of femoral strength in white women and men. J Bone Miner Res (2010) 2.03
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol (2007) 2.02
Characterizing the risk assessment of heavy metals and sampling uncertainty analysis in paddy field by geostatistics and GIS. Environ Pollut (2005) 2.00
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res (2011) 1.99
Structural determinants of vertebral fracture risk. J Bone Miner Res (2007) 1.97
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res (2011) 1.95
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Signaling within a coactivator complex: methylation of SRC-3/AIB1 is a molecular switch for complex disassembly. Mol Cell Biol (2006) 1.94
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res (2009) 1.94
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Four cases of Graves' disease which developed after painful Hashimoto's thyroiditis. Intern Med (2006) 1.90
In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res (2014) 1.90
Cellular energy depletion resets whole-body energy by promoting coactivator-mediated dietary fuel absorption. Cell Metab (2011) 1.89
Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun (2005) 1.89
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation (2005) 1.88
Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol (2004) 1.87
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
Reproductive functions of progesterone receptors. Recent Prog Horm Res (2002) 1.82
Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell (2005) 1.82
Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res (2002) 1.81
Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am (2005) 1.80
The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. Proc Natl Acad Sci U S A (2008) 1.80
CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol Cell Biol (2004) 1.77
Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem (2003) 1.76
The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol (2008) 1.75
Proteomic analysis of steady-state nuclear hormone receptor coactivator complexes. Mol Endocrinol (2005) 1.74
Bone structure at the distal radius during adolescent growth. J Bone Miner Res (2009) 1.74
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology (2010) 1.74
Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol (2003) 1.73
Optimization-based reconstruction of sparse images from few-view projections. Phys Med Biol (2012) 1.72
Streamlined analysis schema for high-throughput identification of endogenous protein complexes. Proc Natl Acad Sci U S A (2010) 1.72